Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.12 USD
Change Today +0.0019 / 1.58%
Volume 51.8K
RGDX On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1640 Marengo Street

7th Floor

Los Angeles, CA 90033

United States

Phone: 323-224-3900

Fax: 323-224-3096

Response Genetics, Inc., a life sciences company, engages in the research and development of clinical diagnostic tests for cancer. The company primarily sells its ResponseDX diagnostic tests and provides clinical trial testing services to pharmaceutical companies. The company’s proprietary technologies enable it to extract ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) from tumor specimens that are stored as formalin-fixed and paraffin-embedded (FFPE) specimens and thereby to analyze genetic information contained in these tissues. The company’s technologies also enable it to use the FFPE patient biopsies for the development of diagnostic tests. New Offerings During 2014, the company added six additional tests to its ResponseDX offering, such as isocitrate dehydrogenase 1 (IDH1)/isocitrate dehydrogenase 2 (IDH2), MGMT (O6-methylguanine DNA methyltransferase), EGFRvIII, 1p/19q (1p and 19q), PTEN (phosphatase and tensin homolog) and PDGFRA (Platelet Derived Growth Factor Receptor A). In addition, the company expanded its suite of profiles to include brain cancer testing and upgraded its KRAS and NRAS tests with additional mutation coverage. ResponseDX: Glioma In 2014, the company launched a menu of molecular diagnostic tests for glioma. The company’s glioma panel includes FISH (fluorescence in situ hybridization), PCR (polymerase chain reaction), methylation-specific PCR, and sequencing-based tests. The company has offering for glioma among commercial laboratories. EGFRvIII Mutation EGFRvIII is an oncogenic mutant form of epidermal growth factor receptor (EGFR) expressed in approximately 25-30% of glioblastoma patients. Patients exhibiting EGFRvIII expression define a prognostically distinct subgroup of glioblastomas associated with favorable survival, and response to tyrosine kinase inhibitor therapy. In 2014, the company launched an EGFRvIII mutation test by Real-Time PCR to detect the presence of EGFRvIII in the EGFR gene. 1p/19q Deletion Loss of part or all of the 1p/19q chromosome arms occurs frequently in various subtypes of gliomas. 1p/19q loss is diagnostic for oligodendroglioma, and helps to determine sensitivity to response to chemotherapy, radiation and temozolomide treatment. In 2014, the company launched a 1p/19q FISH test to detect deletion of these chromosome arms. IDH1 and IDH2 Mutations Mutations in human IDH1 and IDH2 genes exist in the majority of grade 2 and 3 gliomas and secondary glioblastomas, and have prognostic relevance, predicting survival for patients affected by astrocytomas, oligodendrogliomas, and glioblastomas. In 2014, the company introduced a Sanger Sequencing test for mutations in the IDH1 and IDH2 genes. MGMT Methylation The MGMT gene encodes a DNA repair enzyme. Methylation of MGMT is associated with a favorable response to alkylating chemotherapy in patients diagnosed with glioma, and in 2013, the National Comprehensive Cancer Network (NCCN) Guidelines recommended the use of temozolomide as adjuvant therapy in patients with MGMT gene methylation. In 2014, the company launched a test to identify the methylation status of the MGMT gene by Real-Time Methylation Specific PCR. PTEN Loss of the Phosphatase and tensin homolog (PTEN) gene is frequently observed in various types of cancers, including breast, colorectal, endometrial, glioblastoma, head and neck, kidney, lung, melanoma, ovarian, pancreatic, prostate and thyroid. PTEN loss is associated with decreased survival in patients diagnosed with glioblastoma, gastrointestinal stromal tumors and breast carcinomas and correlates with resistance to anticancer therapies, primarily treatments targeting receptor tyrosine kinases, including trastuzumab, gefitinib and cetuximab. In 2014, the company launched a test to detect PTEN loss by FISH. PDGFRA Mutations in the PDGFRA gene are found in gastrointestinal stromal tumors (GIST) and melanomas, and tend to be mutually exclusive with cKIT mutations. The NCCN Guidelines recommend cKIT/PDGFRA testing for GIST prior to targeted molecular therapies, such as imatinib and sunitinib. In 2014, the company introduced a Sanger Sequencing test for PDGFR


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGDX:US $0.12 USD +0.0019

RGDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $10.67 USD -0.08
Psychemedics Corp $12.02 USD +0.12
Rosetta Genomics Ltd $3.07 USD +0.07
Signal Genetics Inc $1.56 USD -0.08
Veracyte Inc $11.60 USD +0.47
View Industry Companies

Industry Analysis


Industry Average

Valuation RGDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESPONSE GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at